[#DIV28SUPER] Call for Division 28 archival materials

Hi all,

I'm sending the email below on behalf of Ty Schepis, our division Archivist.

Thank you,

Matt

-----------------------------------------------------------------

Dear Members of APA Division 28,

 

The division is working to create an accessible archive of division records and other materials, with the ultimate goal of making this accessible to the entire membership of the division. As a first step, however, we need to collect all materials that are relevant to the division, including board minutes, committee minutes or reports, and any other information that would be worth including in an archive. As the division's Archivist, you can send those materials directly to me (schepis@txstate.edu). Alternatively, if the materials are housed in a cloud storage system like Box, Google Drive, or something similar, you can grant me access to the folder(s), and I can pull the materials that way. Please note that my institution has email file size restrictions, so if you send any big files they may bounce back. In that event, we can use a file transfer service as needed.

 

Please let me know if you have any questions, and thanks for your help with this divisional initiative!

Best wishes,

Ty Schepis

[#DIV28SUPER] AHRQ releases draft systematic review for public comment on ADHD diagnosis and treatment in children and adolescents

Dear Colleagues,

 

The Agency for Healthcare Research and Quality’s Effective Health Care Program recently posted an opportunity to comment on its draft systematic review ADHD Diagnosis and Treatment in Children and Adolescents. The draft systematic review is available for review and public comment until July 24, 2023.

 

The purpose of the review is to assess the evidence on the diagnosis, treatment, and monitoring of ADHD in children and adolescents to inform a planned update of the American Academy of Pediatrics guidelines.

 

Please submit any comments you may have directly to the website at https://effectivehealthcare.ahrq.gov/products/attention-deficit-hyperactivity-disorder/draft-report.

 

You are also invited to share your submitted comments with us to help inform comments submitted from our office. If you wish to share your submitted feedback, please send your comments to Jacob Marzalik at jmarzalik@apa.org by the end of the day July 21, 2023.

 

Please share widely with your networks.

 

Thank you,

 

 

Jacob S. Marzalik, MA (he/him/his)

Project Manager, Clinical Practice Guidelines

Practice Transformation and Quality, Practice Directorate

American Psychological Association

  

750 First Street NE, Washington DC 20002-4242

202-336-5872 | jmarzalik@apa.org

 

APA Land and Labor Acknowledgement
The APA central office in Washington, DC sits on the occupied territory of the Nacotchtank and Piscataway peoples who were forcibly displaced in the 1600s. We pay respects to their elders past and present.

We also acknowledge the unpaid and forced servitude of enslaved Africans and their descendants whose unremittent labor and exploitation were pivotal to the economic growth of our nation and many of whom face ongoing oppression, racism, and violence. We recognize the broken promises and harm done to the first peoples of these lands, the horrors of American slavery, and the painful legacies of inequity affecting many groups that continue to persist.

 

[#DIV28SUPER] Fwd: [DIVTRIO] Influencer Events at the upcoming APA Convention

FYI

Begin forwarded message:

From: FRANK FARLEY <frank.farley@COMCAST.NET>

Subject: [DIVTRIO] Influencer Events at the upcoming APA Convention

Date: June 4, 2023 at 5:17:57 PM EDT

To: DIVTRIO@LISTS.APA.ORG

Reply-To: APA Division Presidential trios communicating about divisional topics <DIVTRIO@LISTS.APA.ORG>

      External Email - Use Caution      

Dear Division Leaders,

The Convention approaches, 8 weeks to go (it's August 3-5). You and your members might find the following 4 sessions of special interest focusing on  major influential contributors to our great discipline.. Each session is a conversation of 50 minutes between the invitee and myself. The first three sessions are all in the same room one after the other (Convention Center Level 1, Room 146c) on Thursday August 3 beginning at 1:00 PM and ending at 3:50PM, just in time to head for the Social Hours and continue  the conversations among your convention colleagues! (NB:The 4th session is on Saturday). These sessions are contributions of Division 26 (Ellis, Pinker) and Division 46 (Chomsky, Evans). The sessions are as follows:

 

 

1) 1:00 PM, Thursday:Rm 146c, Remembering Albert Ellis--Legacy and Life.       Debbie Joffe Ellis     

                                        

2) 2:00 PM, Thursday, Rm 146c, Steven Pinker, Harvard University

 

3) 3:00 PM, Thursday, Rm 146c, Noam Chomsky, University of Arizona & MIT

 

4) 1:00 PM,  Saturday, Rm 147b, Arthur Evans, CEO & Executive VP, APA

 

Join me, it'll be fun, stimulating AND informative!

 

Frank

Former President, APA and Divisions 26,1,3,10,15,32,46,48,52

 

 

 

Click on this link to unsubscribe from the DIVTRIO list UNSUBSCRIBE

An email will automatically open with "Unsubscribe" in the subject area. Just Send the message, as is, to unsubscribe from this list.

[#DIV28SUPER] FW: Approval of draft NIDA Neuroscience Update

Please see the following funding opportunity announcements from the National Institute on Drug Abuse:

 

Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional) RFA-DA-23-012

This Funding Opportunity Announcement (FOA) supports research on the effects of HIV and addictive substances, acting independently or synergistically on blood brain barrier (BBB) structure and function and the involvement of these effects in HIV associated neuropathology.

 

Application Due Date: August 10, 2023

 

------------

Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)  RFA-DA-24-001.

 

This Notice of Funding Opportunity (NOFO) invites grant applications aimed at elucidating pathophysiological mechanisms of HIV-associated neurological disorders (HAND) using ex vivo culturing platforms in the presence of addictive substances, with emphasis on genetic, epigenetic and neuroimmune mechanisms at the single cell to neural circuit levels.

 

Application Due Date: August 10, 2023

 

----------------

Advancing Psychedelics Research for Treating Addiction (R01 Clinical Trial Not Allowed)  RFA-DA-24-028  
This notice of funding opportunity (NOFO) will support research to improve our understanding of psychedelic drug mechanisms in the context of substance use disorders (SUDs). This NOFO will also support the design and synthesis of chemical biology tools and probes to aid basic research on psychedelics and their translational pharmacology.

Note: This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.

 

Application Due Date: November 02, 2023

 

 

Other NIDA Funding Opportunities: https://nida.nih.gov/funding/nida-funding-opportunities

 

------

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L

 

[#DIV28SUPER] postdoc at VTC

Dear Colleagues-

Please find attached an ad for a postdoc at VTC.

-Bill. 

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383

Professor
Departments of Behavioral Science, Psychiatry and Psychology
Center on Drug and Alcohol Research
University of Kentucky

Director
Regulatory Knowledge and Support Core-Center for Clinical and Translational Science

Clinical Research Support Office

Associate Director for Clinical Research

Substance Use Priority Research Area

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

[#DIV28SUPER] Fwd: National Institute on Drug Abuse (NIDA) Job Opening

Begin forwarded message:

From: "Aklin, Will (NIH/NIDA) [E]" <aklinwm@nida.nih.gov>

Subject: National Institute on Drug Abuse (NIDA) Job Opening

Date: May 2, 2023 at 4:21:10 PM EDT

To: 'Ryan Vandrey' <rvandrey@jhmi.edu>

      External Email - Use Caution      

Hi Ryan,

 

I hope you are well. Please note and share this Federal job opening with interested Division 28 colleagues.

 

NIDA Division of Therapeutics and Medical Consequences (DTMC) is hiring a Health Scientist Administrator (Substance Use Disorders)

 

The National Institute on Drug Abuse (NIDA), Division of Therapeutics and Medical Consequences (DTMC) is hiring a Health Scientist Administrator focused on clinical research. DTMC administers studies to identify and evaluate the efficacy and/or safety of medications, devices, digital, behavioral, or other therapeutic interventions for substance use disorders (SUDs) and to study the medical consequences of SUDs.

 

In this role, the candidate will provide strategic guidance on potential therapies and technical matters pertaining to the development of treatments for SUDs and program activities for a large research portfolio of grants, cooperative agreements, and contracts. The ideal candidate will have an advanced degree in psychology, psychiatry, pharmacology, or biomedical related field.      

 

Interested candidates are encouraged to apply to the Global Health Scientist Administrator vacancy announcement on USA Jobs (https://www.usajobs.gov/) on May 15^th, 2023. For more information, please contact Will M. Aklin, Ph.D., Chief, Clinical Research Grants Branch, Division of Therapeutics and Medical Consequences, NIDA aklinwm@mail.nih.gov, or 301-827-5909.

 

Best regards,

Will

 

--

Will M. Aklin, Ph.D.

Chief, Clinical Research Grants Branch

Director, Behavioral Therapy Development Program (BTDP)

Division of Therapeutics and Medical Consequences (DTMC)

National Institute on Drug Abuse 

National Institutes of Health

3WFN, Room 08A18, MSC 6016 

301 North Stonestreet Avenue 

Bethesda, MD 20892

301-827-5909

aklinwm@mail.nih.gov

[#DIV28SUPER] Innovation for Substance Use Disorder (I4SUD)- apply now!

Greetings colleagues, 

Please see below an opportunity to participate in a free entrepreneurial training program for persons in the SUD field. Just having an idea or interest in learning more about commercialization in the SUD space is all you need.

---

 

View this email in your browser

Our application is open!   Innovations for Substance Use Disorders is a newly launched Executive Education certificate program for participants to work individually or in teams to assess if their ideas and inventions can be transformed into innovations to address problems in SUDs.   The virtual program features asynchronous and synchronous online activities; a multi-day visit to Carey's Baltimore - Inner Harbor location for workshops, clinical site visits, and community building. Live sessions and virtual mentoring will occur from August 28 - October 16, 2023. The in-person visit with expert panels, community building, SUD clinic visits, and a pitch competition will take place October 17 - October 20, 2023. All participants will have their airfare, meals, and accommodations covered by the sponsoring grant.   The program is open to U.S.-based participants only.

Apply Here